News

The agency disclosed a tranche of more than 200 complete response letters from the past five years, but only those involving ...
The FDA has released an "initial batch" of 200 complete response letters (CRLs) in efforts to boost transparency. | The FDA has released an "initial batch" of 200 complete response letters (CRLs) in ...
Investors have long asked the FDA to share its reasons for rejecting drugs, arguing that companies can use the agency’s silence on the matter to mislead the market.
The U.S. FDA publishes over 200 complete response letters to enhance transparency within the agency. Read more here.